Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma

美波利祖马布 医学 哮喘 内科学 逻辑回归 嗜酸性 儿科 物理疗法 嗜酸性粒细胞 病理
作者
Yuto Hamada,Dennis Thomas,Erin S. Harvey,Sean Stevens,Michael Fricker,Hayley Lewthwaite,Vanessa M. McDonald,Andrew Gillman,Mark Hew,Vicky Kritikos,John W. Upham,Peter G. Gibson
出处
期刊:The European respiratory journal [European Respiratory Society]
卷期号:65 (1): 2400782-2400782 被引量:14
标识
DOI:10.1183/13993003.00782-2024
摘要

BACKGROUND: Patients with severe eosinophilic asthma, characterised by a high disease burden, benefit from mepolizumab, which improves symptoms and reduces exacerbations, potentially leading to clinical remission in a subgroup. This study aimed to identify treatment response trajectories to mepolizumab for severe eosinophilic asthma and to assess the achievement of clinical remission. METHODS: Data from the Australian Mepolizumab Registry were used to assess treatment responses at 3, 6 and 12 months. The treatment response trajectories were identified using a group-based trajectory model. The proportions achieving clinical remission at 12 months, which was defined as well-controlled symptoms, no exacerbations and no oral corticosteroid (OCS) use for asthma management, were compared between trajectories, and baseline predictors of the trajectories were identified using logistic regression analysis. RESULTS: We identified three trajectory groups: Group 1, "Responsive asthma with less OCS use" (n=170); Group 2, "Responsive late-onset asthma" (n=58); and Group 3, "Obstructed and less responsive asthma" (n=70). Groups 1 and 2 demonstrated higher proportions achieving clinical remission at 36.5% and 25.9%, respectively, compared to Group 3 with 5.7% (p<0.001). Baseline predictors for assigned groups included lower OCS dose in Group 1; greater forced expiratory volume in 1 s percentage predicted, higher Asthma Quality of Life Questionnaire score, higher OCS dose and nasal polyps in Group 2; with Group 3 as the reference. CONCLUSIONS: Treatment response to mepolizumab in severe eosinophilic asthma follows three trajectories with varying proportions achieving clinical remission and differing baseline characteristics. Treatment response variability may influence the achievement of clinical remission with mepolizumab therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
零零五完成签到,获得积分10
刚刚
1秒前
1秒前
2秒前
123完成签到,获得积分10
2秒前
2秒前
3秒前
恐怖稽器人完成签到,获得积分10
3秒前
zeroayanami0完成签到,获得积分10
3秒前
4秒前
11完成签到,获得积分10
5秒前
现代雪晴完成签到,获得积分10
5秒前
sssyz发布了新的文献求助10
5秒前
dogking发布了新的文献求助10
5秒前
腼腆的戾发布了新的文献求助10
6秒前
5tcl完成签到,获得积分10
6秒前
cxyyy完成签到,获得积分10
6秒前
6秒前
lele发布了新的文献求助10
6秒前
香蕉觅云的应助被123采纳,获得10
7秒前
7秒前
7秒前
yy发布了新的文献求助30
7秒前
7秒前
8秒前
LZ发布了新的文献求助10
9秒前
不再挨训完成签到 ,获得积分10
9秒前
9秒前
9秒前
星空发布了新的文献求助10
9秒前
10秒前
王培德完成签到 ,获得积分10
10秒前
zz完成签到,获得积分10
11秒前
腼腆的戾完成签到,获得积分10
11秒前
77完成签到 ,获得积分10
12秒前
zhangzz发布了新的文献求助10
12秒前
今后的应助被sh131采纳,获得10
12秒前
12秒前
小武发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185894
求助须知:如何正确求助?哪些是违规求助? 9574569
关于积分的说明 21836585
捐赠科研通 7783675
什么是DOI,文献DOI怎么找? 3434685
关于科研通互助平台的介绍 2559031
邀请新用户注册赠送积分活动 2481484